All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
EBMT 2018 | Allo-HSCT from unrelated cord blood or haploidentical donor grafts in sAML patients
Annalisa Ruggeri from Hôpital Saint-Antoine, Paris, FR, presented at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Lisbon, Portugal on behalf of colleagues data from a retrospective study which evaluated the outcomes of secondary acute myeloid leukemia (sAML) patients who underwent allogeneic hematopoietic cell transplantation (allo-HSCT) from either an unrelated umbilical cord blood (UCBT) or haploidentical (Haplo) donor.
In this study, the outcomes of 409 adult sAML patients who received either UCBT (n = 163, median age at transplant = 56 years) or Haplo (n = 246, median age at transplant = 59.7 years) transplantation at EBMT centers between 2007–2016 were retrospectively compared. The median follow-up time for the UCBT or Haplo groups were 24.3 (3.0–112.3) months and 16.9 (2.5–101.0) months respectively.
Key findings:
- Cumulative incidence of grade II–IV acute graft versus host disease (GvHD) at 100 days in the UCBT and Haplo group: 33% vs 23%, P = 0.018
- 2-year cumulative incidence of chronic GvHD in the UCBT and Haplo group: 26% vs 26%, P = 0.706
- 2-year relapse incidence in the UCBT and Haplo group: 33% vs 30%, P = 0.380
- 2-year non relapse mortality (NRM) rate in the UCBT and Haplo group: 34% vs 41%, P = 0.711
- 2-year survival in the UCBT and Haplo groups respectively
- Leukemia-free survival (LFS): 26% vs 36%, P = 0.235
- Overall survival (OS): 29% vs 41%, P = 0.246
- Compared to Haplo, UCBT associated significantly with higher risk of grade II-IV acute GVHD (HR = 1.9, P = 0.009) and lower GHVD-free-relapse-free-survival (HR = 1.57, P = 0.007)
In summary, Haplo transplantation associated with a lower acute GvHD and higher GRFS. However, there were no significant differences in OS, LFS, relapse, NRM and chronic GvHD between the Haplo and UCBT groups.
The speaker concluded by stating that the findings of this retrospective study demonstrate that both Haplo and UCBT transplant strategies are “valid options for patients” with sAML.
References